BPC-157 Dosage and Protocol Guide: Injection, Timing, and Cycle (2026)

Executive Summary

BPC-157 dosage and protocol questions are among the most-searched topics in the peptide space — because while information about the peptide's potential benefits is widely available, specific guidance on how to take it correctly is not. This guide fills that gap with a structured breakdown of dosing routes, standard dose ranges, injection technique, timing strategy, cycle structure, and what clinical monitoring a legitimate protocol requires.

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a gastric protein. Its most studied effects in preclinical research involve accelerated tissue repair across muscle, tendon, ligament, bone, gut, and nerve tissue. In US telehealth, it is available by prescription from compounding pharmacies and is primarily used for musculoskeletal recovery, gut dysfunction, and as part of broader regenerative protocols.

Before reviewing protocol specifics, note that BPC-157 is not FDA-approved. It is available only through licensed US compounding pharmacies via physician prescription. The dosing parameters below reflect commonly prescribed telehealth protocols as of 2026 — they are not a substitute for individualized clinical guidance. Use this guide alongside our provider comparison tool, BPC-157 overview, and BPC-157 benefits and dosage overview.

At-a-Glance Comparison

Standard BPC-157 dosing parameters by route as of 2026. Individual dosing should be determined by a licensed prescribing provider based on condition, weight, and response.

Understanding BPC-157 Routes: Subcutaneous vs. Oral vs. Intramuscular

Route selection depends on what you are treating, not just personal preference. Each route delivers BPC-157 differently and is suited to different clinical goals. Buyers searching for bpc-157 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Subcutaneous injection (SC) is the most common route in telehealth — it delivers BPC-157 systemically through absorption into subcutaneous fat. It is used for systemic effects (whole-body recovery, anti-inflammatory, gut protection) as well as localized effects. Intramuscular or perilesional injection places the peptide directly near the target tissue — this approach is favored for specific musculoskeletal injuries (tendon rupture, muscle tear, joint pathology) where high local concentration is the objective. Oral BPC-157 (typically as the arginate salt form, which has improved gut stability) is primarily used for gastrointestinal indications — leaky gut, IBD, NSAID-related gut damage, and esophageal or stomach healing. Oral bioavailability for standard BPC-157 is limited due to enzymatic degradation, which is why the arginate formulation or higher oral doses are used. Some protocols use both SC and oral concurrently — SC for systemic effects plus oral for direct gut contact. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Do not attempt intramuscular injection near joints without clinical guidance — incorrect needle placement near tendons or neurovascular structures carries real risk. Perilesional (near-site) injection should only be performed if instructed and trained by your provider. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Step-by-Step Subcutaneous Injection Protocol

Most telehealth BPC-157 patients use subcutaneous injection. Here is the standard technique used by peptide clinic patients in 2026. Buyers searching for bpc-157 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

1. Wash hands thoroughly with soap and water. 2. Wipe the rubber stopper of the vial with an alcohol swab; let dry 10–15 seconds. 3. Draw air into the syringe equal to your dose volume. 4. Insert needle into the vial, inject air, then draw out your dose. 5. Remove needle from vial; check for air bubbles — tap syringe and push bubbles out. 6. Clean injection site with alcohol swab; common sites are abdomen (1–2 inches from navel), outer thigh, or lower back fat. 7. Pinch 1–2 inches of skin. Insert needle at 45–90 degree angle. 8. Inject slowly and steadily. 9. Remove needle; apply light pressure with clean gauze or cotton. 10. Dispose of needle safely in a sharps container. Rotate sites each injection to prevent irritation or lipodystrophy. Standard insulin syringes (28–31G, 1 mL) are used for most peptide injections. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Common injection-site reactions (redness, mild swelling) are normal and resolve in hours. Persistent nodules, increasing redness, or warmth suggest possible contamination — contact your provider. Never reuse needles. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Reconstituting BPC-157: How to Mix the Powder

BPC-157 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Getting this right ensures dosing accuracy. Buyers searching for bpc-157 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Standard vials are 5 mg. To reconstitute: draw 2 mL of bacteriostatic water into a syringe. Inject it slowly into the vial — let it run down the glass, do not inject directly onto the powder. Gently swirl (do not shake) until the powder fully dissolves. The solution should be clear and colorless. At 2 mL per 5 mg vial, concentration is 2,500 mcg/mL. Dose math: for a 250 mcg dose, draw 0.1 mL (10 units on a 100-unit insulin syringe). For 500 mcg, draw 0.2 mL (20 units). Some providers use 1 mL of bacteriostatic water (5,000 mcg/mL) for more concentrated solutions — the concentration changes the volume drawn per dose, so always recalculate when changing reconstitution volume. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Using regular sterile water instead of bacteriostatic water means no preservative — solution should be used within 24–48 hours or discarded. Bacteriostatic water with benzyl alcohol extends stability to approximately 30 days refrigerated. Never use tap water or saline intended for IV use. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Dosage by Condition: What Protocols Look Like in Practice

Dosing is not one-size-fits-all. Providers tailor BPC-157 dosing to the condition, severity, body weight, and response. Here is what commonly prescribed protocols look like for the most common use cases. Buyers searching for bpc-157 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Musculoskeletal injury (acute): 300–500 mcg once or twice daily, subcutaneous near the injured area or systemically, for 4–8 weeks. Higher-end dosing and BID frequency are used for acute severe injuries; maintenance doses drop to once daily as healing progresses. Gut healing (leaky gut, IBD, NSAID damage): 250–500 mcg subcutaneous once daily, or 500 mcg–1 mg oral (arginate form) once or twice daily. Some protocols combine both routes. Duration: 4–12 weeks depending on severity. General recovery / anti-inflammatory: 200–300 mcg subcutaneous once daily. Often combined with other peptides (TB-500 for systemic tissue repair, sermorelin or CJC/Ipa for GH optimization). Duration: 8–12 weeks with a 4-week break before repeating. Neuroprotection / TBI: Experimental; typically 200–500 mcg SC once daily. This application has the least clinical evidence in humans — discuss risk/benefit carefully with your provider. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Higher doses are not necessarily better — BPC-157 appears to have a bell-shaped dose-response curve in some preclinical models. Standard clinical doses (200–500 mcg) are used because they fall within the effective range without pushing into potential negative feedback territory. Always start at the lower end and adjust with provider guidance. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Timing: When to Take BPC-157

Unlike GH peptides where timing around GH pulses matters significantly, BPC-157 timing is more flexible — but there are still best practices that maximize effect and tolerability. Buyers searching for bpc-157 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Subcutaneous BPC-157 can be taken at any time of day — fasted or fed. The peptide is not insulin-sensitive in the way GH secretagogues are, so eating before injection does not blunt its effect. That said, many providers recommend morning injection for consistency and easy adherence tracking. BID protocols commonly use morning and evening. For gut-specific oral protocols, taking on an empty stomach allows the peptide to contact the gut lining directly before food content interferes. If using BPC-157 alongside GH peptides (e.g., CJC-1295/Ipamorelin), most providers administer them at different times — GH peptides before bed fasted, BPC-157 in the morning. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: There is no known drug-food interaction that requires fasting for injectable BPC-157. However, if combining with other peptides that are food-sensitive (GHRP/GHRH analogs), be careful not to dose all peptides at the same time without provider guidance on sequencing. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Cycle Length, Breaks, and Ongoing Use

How long should a BPC-157 cycle run? The answer depends on the indication — acute injury protocols are shorter; maintenance and gut protocols may run longer. Buyers searching for bpc-157 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Standard cycle structure: 4–12 weeks on, followed by a 2–4 week break before reassessing or repeating. Acute injury: 4–6 weeks at higher doses; reassess at week 4. If injury resolves, taper to low-dose maintenance or stop. Chronic/recurrent issues: 8–12 weeks on, 4 weeks off, repeat as needed. Gut healing: 8–12 weeks; some providers maintain longer-duration low-dose oral protocols for chronic IBD or leaky gut. Anti-aging/general wellness: 8 weeks on, 4 weeks off; some run continuous protocols at low doses (200 mcg once daily) with periodic 2-week breaks. There is no strong human evidence base for optimal cycle lengths — the above reflects standard US telehealth practice. Long-term safety data beyond 6–12 months are not available. Annual monitoring labs (metabolic panel, CBC) are standard at responsible clinics. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Continuous indefinite use without breaks is generally not recommended given the absence of long-term safety data. Providers who prescribe BPC-157 without periodic reassessment or without offering monitoring labs should be viewed with skepticism. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If you are evaluating BPC-157 as part of a recovery, gut healing, or anti-aging protocol, the right starting point is a licensed provider consultation with baseline labs. Our provider comparison tool helps you find telehealth clinics that prescribe peptides responsibly — with verified US compounding pharmacies, written protocols, and follow-up monitoring.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is the standard BPC-157 dosage?

The most commonly prescribed subcutaneous dose is 200–500 mcg per injection, with 250 mcg once daily being a typical starting point for systemic use. Higher doses (300–500 mcg BID) are used for acute musculoskeletal injuries. Oral dosing is higher due to lower bioavailability — typically 500 mcg–1 mg per day of the arginate salt form.

How do I inject BPC-157 subcutaneously?

Use a 28–31G insulin syringe. Clean the injection site and vial stopper with alcohol. Draw your dose. Pinch 1–2 inches of skin at the injection site (abdomen, outer thigh, or lower back fat). Insert the needle at a 45–90 degree angle. Inject slowly, remove, and apply light pressure. Rotate sites each injection. Dispose of the needle in a sharps container.

How do I reconstitute BPC-157?

Draw 2 mL of bacteriostatic water into a syringe. Inject it slowly into the lyophilized BPC-157 vial. Swirl gently until dissolved — do not shake. The resulting concentration is 2,500 mcg/mL. For a 250 mcg dose, draw 0.1 mL (10 units on an insulin syringe). Store reconstituted vials refrigerated and use within 30 days.

Should I take BPC-157 fasted or with food?

Injectable BPC-157 can be taken fasted or fed — it is not GH-pathway-sensitive in the way GHRH/GHRP peptides are. Most patients take it in the morning for consistency. Oral BPC-157 is typically taken on an empty stomach to allow direct gut contact before food content arrives.

How long should a BPC-157 cycle be?

Standard cycles are 4–12 weeks depending on the indication. Acute musculoskeletal injuries typically use 4–6 week protocols at higher doses. General recovery and gut healing protocols run 8–12 weeks. Take a 2–4 week break between cycles. There is no strong evidence base for optimal cycle length — follow your provider's protocol and reassess at the midpoint.

Can I inject BPC-157 near the injury site?

Yes — perilesional or local subcutaneous injection near the injury site is used for targeted musculoskeletal applications (tendon, ligament, muscle). This is distinct from intramuscular injection and can be done by most patients following proper training. Injection near joints or deep tissue structures should only be done with provider guidance.

What is the difference between BPC-157 and BPC-157 arginate?

Standard BPC-157 is poorly stable in the GI tract when taken orally — stomach acid and enzymes degrade much of it before it can be absorbed. BPC-157 arginate (or the stable salt form) has improved gut stability, making it more suitable for oral administration. It is typically used in oral protocols for gut healing. Injectable BPC-157 does not require the arginate form.

What side effects should I watch for?

BPC-157 has a favorable tolerability profile at standard doses. Common: mild injection site reactions (redness, swelling), temporary nausea with oral dosing. Uncommon: dizziness, headache. BPC-157 does not significantly affect cortisol, prolactin, or sex hormones. No major safety signals have emerged in clinical use at standard doses. Contact your provider if you develop unusual symptoms — especially any rapid growth of existing lesions (theoretical concern given its tissue-repair mechanisms).

Can I stack BPC-157 with other peptides?

Yes — BPC-157 is commonly stacked with TB-500 for musculoskeletal repair (they have complementary mechanisms), and with GH peptides (CJC-1295/Ipamorelin) for broader recovery and anti-aging protocols. When stacking, administer peptides at different times of day if they have different timing requirements. Always disclose your full protocol to your provider.

Where can I get BPC-157 prescribed?

BPC-157 requires a prescription from a licensed physician and is dispensed by US compounding pharmacies. Look for telehealth providers that require baseline labs, provide written dosing protocols, use verified US compounding pharmacies (503A or 503B), and offer follow-up monitoring. Our provider comparison tool and best peptide clinics 2026 guide are the best places to start.